Choline forms and physical exercise
Cycling, marching and strength tests in studies of different choline forms.
Key points
- In trained men, a single dose of choline bitartrate showed no convincing advantage in time to exhaustion or work performed in two cycling protocols. This comparison does not support expecting a confirmed improvement in cycling performance. [1] See the evidence 1 2
- In a seven-day study of 48 young men, α-GPC showed no advantage over placebo in lower-body isometric strength. Based on this comparison, a confirmed increase in lower-body isometric strength over seven days should not be expected when choosing α-GPC. [2] See the evidence 1
- In the same study a difference in jump power was found between 250 and 500 mg α-GPC doses, not as an established advantage over placebo. When comparing results distinguish dose comparisons from comparisons with placebo. [2] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Different forms and physical tests were studied in separate comparisons.
Key points
Why these conclusions
Exercise test results
Trained men took a single 2.43 g dose of choline bitartrate in a drink one hour before cycling. Time to exhaustion and work performed in two protocols did not differ substantially from the comparison. [1]
In another trial participants received choline citrate before and during a march; no advantage was found in running to exhaustion or squats after the march. [3]
Young men received α-GPC at 250 or 500 mg per day for seven days; caffeine and placebo were assessed separately. No advantage of α-GPC in lower-body isometric strength was shown; a difference in jump power was found between doses, not as an advantage over placebo. [2]
Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC have different compositions and amounts of elemental choline; results for one form do not transfer to another. [4] [5] [6] [2]
Time to exhaustion did not differ substantially in the two cycling tests.
| Parameter | Data |
|---|---|
| Result | Time to exhaustion did not differ substantially in the two cycling tests. Time to exhaustion was similar in both cycling protocols. |
| Participants | 20 trained men aged 23–29, 10 each at 150% and 70% VO₂max |
| Form | Choline bitartrate 2.43 g in a drink, orally |
| Dose | Choline bitartrate 2.43 g in a drink, orally |
| Dose basis | Choline bitartrate 2.43 g in a drink, orally |
| Comparator | The same drink without choline |
| Duration | Single dose one hour before, crossover protocol |
| Confidence | 2/4: Precision: two groups of 10 and CI not extracted.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: available reporting is insufficient to assess concealment and analysis. |
| Evidence base | 1 trial |
| Sources | [1] |
Work performed did not differ substantially in the two cycling tests.
| Parameter | Data |
|---|---|
| Result | Work performed did not differ substantially in the two cycling tests. Work performed was similar in both cycling protocols. |
| Participants | 20 trained men aged 23–29, 10 each at 150% and 70% VO₂max |
| Form | Choline bitartrate 2.43 g in a drink, orally |
| Dose | Choline bitartrate 2.43 g in a drink, orally |
| Dose basis | Choline bitartrate 2.43 g in a drink, orally |
| Comparator | The same drink without choline |
| Duration | Single dose one hour before, crossover protocol |
| Confidence | 2/4: Precision: two groups of 10 and CI not extracted.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: available reporting is insufficient to assess concealment and analysis. |
| Evidence base | 1 trial |
| Sources | [1] |
No advantage in running to exhaustion after the march was found.
| Parameter | Data |
|---|---|
| Result | No advantage in running to exhaustion after the march was found. No significant advantage in running to exhaustion was reported. |
| Participants | 14 participants, 4 hours walking at 5.6 km/h carrying 34.1 kg, 3% incline |
| Form | Choline citrate orally, 8.425 g as described by the source, before and during exertion |
| Dose | Choline citrate orally, 8.425 g as described by the source, before and during exertion |
| Dose basis | Choline citrate orally, 8.425 g as described by the source, before and during exertion |
| Comparator | Placebo in a crossover protocol |
| Duration | One march in each phase |
| Confidence | 1/4: Precision: 14 participants, CI not extracted.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: specific march with a heavy load.; Possible publication bias: no data for a separate downgrade.; Study methods: full dosing regimen and analysis unavailable in the abstract. |
| Evidence base | 1 trial |
| Sources | [3] |
No advantage in squats after the march was found.
| Parameter | Data |
|---|---|
| Result | No advantage in squats after the march was found. No significant advantage in squats was reported. |
| Participants | 14 participants, 4 hours walking at 5.6 km/h carrying 34.1 kg, 3% incline |
| Form | Choline citrate orally, 8.425 g as described by the source, before and during exertion |
| Dose | Choline citrate orally, 8.425 g as described by the source, before and during exertion |
| Dose basis | Choline citrate orally, 8.425 g as described by the source, before and during exertion |
| Comparator | Placebo in a crossover protocol |
| Duration | One march in each phase |
| Confidence | 1/4: Precision: 14 participants, CI not extracted.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: specific march with a heavy load.; Possible publication bias: no data for a separate downgrade.; Study methods: full dosing regimen and analysis unavailable in the abstract. |
| Evidence base | 1 trial |
| Sources | [3] |
No differences in upper-body isometric strength were found among the four groups.
| Parameter | Data |
|---|---|
| Result | No differences in upper-body isometric strength were found among the four groups. No differences in upper-body isometric strength were found among the four groups, p=0.743. |
| Participants | 48 young men, four groups of 12 |
| Form | α-GPC orally 250 or 500 mg/day |
| Dose | α-GPC orally 250 or 500 mg/day |
| Dose basis | α-GPC orally 250 or 500 mg/day |
| Comparator | Placebo, caffeine in a separate group |
| Duration | 7 days |
| Confidence | 1/4: Precision: 12 per group, large SDs and no CIs for pairwise contrasts.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: laboratory measure in a narrow group of young men.; Possible publication bias: no data for a separate downgrade.; Study methods: several tests and comparisons, small group for each dose. |
| Evidence base | 1 trial |
| Sources | [2] |
No advantage of α-GPC over placebo in lower-body isometric strength was found; caffeine was assessed separately.
| Parameter | Data |
|---|---|
| Result | No advantage of α-GPC over placebo in lower-body isometric strength was found; caffeine was assessed separately. In a subsequent comparison of lower-body isometric strength, caffeine differed from placebo, but α-GPC did not. |
| Participants | 48 young men, four groups of 12 |
| Form | α-GPC orally 250 or 500 mg/day |
| Dose | α-GPC orally 250 or 500 mg/day |
| Dose basis | α-GPC orally 250 or 500 mg/day |
| Comparator | Placebo, caffeine in a separate group |
| Duration | 7 days |
| Confidence | 1/4: Precision: 12 per group, large SDs and no CIs for pairwise contrasts.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: laboratory measure in a narrow group of young men.; Possible publication bias: no data for a separate downgrade.; Study methods: several tests and comparisons, small group for each dose. |
| Evidence base | 1 trial |
| Sources | [2] |
No between-group differences in psychomotor vigilance were found.
| Parameter | Data |
|---|---|
| Result | No between-group differences in psychomotor vigilance were found. No between-group differences in psychomotor vigilance were found, p>0.5. |
| Participants | 48 young men, four groups of 12 |
| Form | α-GPC orally 250 or 500 mg/day |
| Dose | α-GPC orally 250 or 500 mg/day |
| Dose basis | α-GPC orally 250 or 500 mg/day |
| Comparator | Placebo, caffeine in a separate group |
| Duration | 7 days |
| Confidence | 1/4: Precision: 12 per group, large SDs and no CIs for pairwise contrasts.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: laboratory measure in a narrow group of young men.; Possible publication bias: no data for a separate downgrade.; Study methods: several tests and comparisons, small group for each dose. |
| Evidence base | 1 trial |
| Sources | [2] |
A power difference was found between the two doses.
| Parameter | Data |
|---|---|
| Result | A power difference was found between the two doses. Changes +151.77±300.54, −143.83±344.03 and +31.29±277.29 N·m/s for 250 mg, 500 mg and placebo respectively. p<0.05 only for 250 versus 500 mg in the specified post hoc analysis. |
| Participants | 48 young men, four groups of 12 |
| Form | α-GPC orally 250 or 500 mg/day |
| Dose | α-GPC orally 250 or 500 mg/day |
| Dose basis | α-GPC orally 250 or 500 mg/day |
| Comparator | 250 mg versus 500 mg; placebo and caffeine in separate groups |
| Duration | 7 days |
| Confidence | 1/4: risk_of_bias: several tests and comparisons, small group per dose.; inconsistency: no comparable independent series for this outcome and comparison.; indirectness: laboratory measure in a narrow group of young men.; imprecision: 12 per group, large SDs and no CIs for pairwise contrasts.; publication_bias: no data for a separate downgrade. |
| Evidence base | 1 trial |
| Sources | [2] |
Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC have different compositions and amounts of elemental choline; results for one form do not transfer to another.
Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC have different compositions and amounts of elemental choline; results for one form do not transfer to another. [4] [5] [6] [2]
More details
What was compared
Comparing α-GPC doses with each other is not the same as comparing either dose with placebo. [2]
Sources
- Effect of choline supplementation on fatigue in trained cyclists. https://pubmed.ncbi.nlm.nih.gov/7674870/
- Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. https://pmc.ncbi.nlm.nih.gov/articles/PMC5629791/
- The effects of choline supplementation on physical performance. https://pubmed.ncbi.nlm.nih.gov/10861337/
- NIH ODS Choline Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
- Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC11782770/
- Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC8349115/
Methodology: Subpages evidence-led supplement pipeline v1